NCT01728285

Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis

A Multicentric Open Randomised, Cross-over Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 261 (actual)
• Sponsor: ALK-Abelló A/S · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Adherence to treatment is crucial to the efficacy of sublingual immunotherapy of allergic diseases. GRAZAX® is a registered drug in Europe, with established efficacy in the treatment of allergic rhinitis, which has to be taken daily by patients. This study was aimed to establish if a device with the characteristics of a mechanical dispenser (Memozax®) could improve adherence to treatment in subjects with hay fever due to allergy to grass

Conditions

• Allergic Rhinitis
• Grass Allergy

Interventions

Type	Name	Description
DEVICE	Electronic compliance device (Memozax®)	An electronic compliance device is distributed to patients allocated to the active arm

Timeline

• Start date: 2007-03-01
• Primary completion: 2009-06-01
• Completion: 2009-10-01
• First posted: 2012-11-19
• Last updated: 2012-11-19

Locations

1 site across 1 country: Italy